DoMore Diagnostics, founded in 2021, is transforming personalized medicine through its innovative use of artificial intelligence. The startup’s slogan, "Personalized medicine made simple with artificial intelligence", encapsulates its mission to democratize access to precise cancer treatment.
Its flagship product, Histotype Px® Colorectal, is a CE-IVDD marked digital biomarker. It’s specifically designed for stage II and III colorectal adenocarcinoma, providing critical support in deciding whether adjuvant chemotherapy is needed post-surgery. This AI-driven tool enhances the role of pathologists, integrating smoothly into existing workflows to improve patient outcomes.
Supported by leading international research and backed by prominent Norwegian tech investors, DoMore Diagnostics stands at the forefront of medical innovation. Its technology, focused on accessibility and integration, positions it as a noteworthy contender in the personalized medicine landscape.